title: Effect of acid-suppressive therapy on Helicobacter pylori production of interleukin-8 in the gastric mucosa.
abstract: BACKGROUND
  Recent studies have shown that acid-suppressive therapy increases the severity of Helicobacter pylori- associated gastritis in the corpus.
  
  
  OBJECTIVE
  To evaluate interleukin (IL)-8 production in the gastric corpus mucosa before and during acid-suppressive therapy in H pylori-infected patients.
  
  
  METHODS
  Ten patients with reflux esophagitis (five H pylori-positive and five H pylori-negative) were treated with omeprazole 20 mg. Serum gastrin concentrations, H pylori colonization density and mucosal IL-8 levels in the corpus were investigated at entry and two weeks after starting therapy. IL-8 levels were measured by ELISA. The organism density was determined, and scored according to area occupied by the bacterial colonies. The presence of H pylori was assessed by rapid urease testing and histological finding of gastric biopsy specimens.
  
  
  RESULTS
  In H pylori-positive patients, concentrations of IL-8 during therapy significantly exceeded those before therapy (36.2+/-6. 8 versus 18.3+/-3.8 pg/mg protein; P<0.05) without altering H pylori density. In H pylori-negative patients, IL-8 levels were similar before and during therapy (6.1+/-2.7 versus 6.3+/-3.0 pg/mg protein). Concentrations of gastrin during therapy were significantly higher than those before therapy in all patients.
  
  
  CONCLUSIONS
  The results suggest that acid suppression increases mucosal IL-8 levels in H pylori-infected patients with reflux esophagitis.
authors.affiliation: Fukuoka Teishin Hospital, Japan. m-yoshi@winter.try-net.or.jp
authors.forename: M
authors.initials: M
authors.lastname: Yoshinaga
authors.forename: A
authors.initials: A
authors.lastname: Ohtani
authors.forename: S
authors.initials: S
authors.lastname: Tsuruta
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: E
authors.initials: E
authors.lastname: Higashi
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: N
authors.initials: N
authors.lastname: Harada
authors.forename: H
authors.initials: H
authors.lastname: Nawata
mesh_terms: D000328:Adult; D000368:Aged; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004942:Esophagitis, Peptic / Q000382:microbiology*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology*; D016481:Helicobacter Infections / Q000378:metabolism*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000494:pharmacology*
chemical_list: D004791:Enzyme Inhibitors; D016209:Interleukin-8; D009853:Omeprazole